1 1

Anti-Human CD20 Monoclonal Antibody (Ofatumumab)

Anti-Human CD20 Monoclonal Antibody (Ofatumumab)

Catalog Number: UA016165 Brand: UA BIOSCIENCE
Share:
Price:
$685 USD
$685 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Human
Synonyms Ofatumumab
Concentration 2mg/mL
Expression System HEK293
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, containing no preservative
Stability & Storage

2 to 8 °C for 2 weeks under sterile conditions;

-20 °C for 3 months under sterile conditions;

-80 °C for 24 months under sterile conditions.

Please avoid repeated freeze-thaw cycles.
Reference

1.Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344.
2.Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025 Sep 11;146(11):1276-1285.

Background

Ofatumumab is a fully humanized monoclonal antibody that targets the CD20 molecule on the surface of B cells. Its core mechanism of action involves binding to the CD20 protein, thereby triggering multiple effector functions—including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis—to efficiently deplete CD20-positive B lymphocytes. Clinically, ofatumumab has a dual application: the intravenous formulation (Arzerra®) is indicated for the treatment of chronic lymphocytic leukemia, while the subcutaneous formulation (Kesimpta®) has been approved for the management of adult relapsing forms of multiple sclerosis, effectively reducing relapse rates and delaying disability progression. Notably, its convenient once‑monthly, at‑home self‑administration regimen offers significant advantages in facilitating long‑term disease management for patients with multiple sclerosis.

Picture

ELISA

Immobilized CD20 Flag&His Tag Protein, Human (Detergent) at 5.0μg/mL (100μL/well) can bind Anti-Human CD20 Monoclonal Antibody (Obinutuzumab) (Cat. No. UA016165) with EC50 of 0.76-1.64 ng/mL.